Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EO2401 vaccine in progressive glioblastoma
NCT04116658Phase 2Completed
- Sponsor
- Enterome
- Start
- Jul 2020
- Primary completion
- Mar 2024
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 4
01
Overview
Phase 2, open-label trial of eo2401 in glioblastoma (GBM) (3 cohorts), sponsored by Enterome. Primary endpoint: Safety and Tolerability of EO2401 Monotherapy, EO2401 in Combination With Nivolumab, EO2401 in Combination With Nivolumab and Bevacizumab at 44 months. Started Jul 2020; status: completed.
02
Drugs
eo2401
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04116658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116658.